Heart Failure
  • CORCINCH:  Randomized clinical evaluation of the AccuCinch Ventricular Restoration System in patients who present with symptomatic heart failure with reduced ejection fraction.  Justin Vader, MD. Ancora Heart.
  • DAPA-ACT HF: Evaluating the Effect of in-hospital initiation of dapagliflozin on clinical outcomes in patients who have been stabilized during hospitalization for acute heart failure.  Justin Hartupee, MD. AstroZeneca Pharmaceuticals LP.
  • DCM Consortium:  Identification of the genetic causes of dilated cardiomyopathy and related conditions.  Gregory Ewald, MD.  Ohio State University.
  • Garden-TIMI:  Investigating symptoms, function, health-related quality of life and safety with repeated subcutaneous administration of ponsegromab v placebo in adult participants with heart failure.  Justin Hartupee, MD. Pfizer Inc. (pending)
  • Lilly:  A single dose study evaluating different dose levels and subcutaneous infusion durations on safety, pharmacokinetics and pharmacodynamics of LY3461767 in participants with chronic heart failure with reduced ejection fraction.  Gregory Ewald, MD.  Eli Lilly and Company.
  • ManageHF: A multifaceted adaptive mobile application to promote self-management and improve outcomes in heart failure.  Gregory Ewald, MD.  University of Michigan.
  • MUSIC-HF:  Phase I/II trial of the safety and efficacy of SRD-001 in subjects with heart failure with reduced ejection fraction.  Gregory Ewald, MD.  Sardocor Corp.
  • MYIA:  Usability and utility assessment of passive remote monitoring of multiple novel indicators of heart failure.  Gregory Ewald, MD.  Healthcare Innovation Lab.
  • REBIRTH:  Randomized evaluation of bromocriptine in myocardial recovery therapy for peripartum cardiomyopathy.  Gregory Ewald, MD.  University of Pittsburgh.
  • REHAB-pEF  Physical Rehabilitation for older patients with acute heart failure with preserved ejection fraction.  Justin Vader, MD.  National Institute of Aging.
  • RESONANCE: Registry of the natural history of recurrent pericarditis in pediatric and adult patients.  Amanda Verma, MD.  Kiniksa Pharmaceuticals.
  • SALUBRIS:  A study to assess the safety and tolerability of JK07 in subjects with heart failure with preserved ejection fraction.  Nancy Sweitzer, MD.  Salubris Biotherapeutics, Inc.
  • SHORE:  Surveillance Heartcare (allomap and allosure) outcomes registry.  Gregory Ewald, MD.  CareDx.
  • TCBR:  Translational cardiovascular biobank and repository.  Gregory Ewald, MD.  Washington University.
  • VICTOR:  Phase 3 study evaluating the efficacy and safety of sGC Stimulator vericiguat in adults with chronic heart failure with reduced ejection fraction.  Gregory Ewald, MD.  Merck Sharp & Dohme LLC
Cardio-Oncology
  • ACE-MOVE:  Registry focusing on diagnosis and innovative treatments to improve outcomes in patients with amyloidosis.  Joshua Mitchell, MD.   Washington University.
  • AG10 OLE:  An open-label extension and safety monitoring study of acoramidis in participants with symptomatic transthyretin amyloid cardiomyopathy who completed the phase 3 ATTRIBUTE-CM trail.  Joshua Mitchell, MD.  Eidos Therapeutics.
  • APOLLO-B:  Phase 3 study evaluating the efficacy and safety of Patisiran in patients with transthyretin amyloidosis with cardiomyopathy.  Joshua Mitchell, MD.  Alnylam Pharmaceuticals.
  • ATRIUM:  Phase 3 study evaluating the efficacy and safety of Abatacept in hospitalized participants with Immune checkpoint inhibitor associated myocarditis.  Joshua Mitchell, MD.  Massachusetts General Brigham/Bristol Myers Squibb. 
  • ATTRIBUTE-CM:  Phase 3 study on the efficacy and safety of AG10 in subjects with symptomatic transthyretin amyloid cardiomyopathy.  Joshua Mitchell, MD.  Eidos Therapeutics.
  • BIOMARKER ANALYSIS IN PATIENTS WITH CANCER:  Prediction of cancer therapeutics related cardiac dysfunction and major adverse cardiovascular events in cancer patients treated with potentially cardiotoxic agents.  Joshua Mitchell, MD.  Washington University.
  • CARDIAC REHAB:  Cardiac Rehabilitation for patients receiving radiation therapy for thoracic cancers.  Shahed Badiyan, MD.  The Foundation for Barnes Jewish Hospital.
  • CARDIOTTRANSFORM:  Phase 3 study evaluating the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).  Joshua Mitchell, MD.  Ionis pharmaceuticals, Inc.
  • CARISMA:  Phase 2 study evaluating tyrosine kinase inhibitor risk-reduction with intensive systolic BP management.  Joshua Mitchell, MD.  ECOG-ACRIN Cancer Research Group.
  • CARING:  Continuous versus intermittent cardiac electrical monitoring in patients with acute promyelocytic leukemia or solid tumor cancer being treated with arsenic trioxide or capecitabine.  Joshua Mitchell, MD.  Washington University.
  • CLARITY:  A study of patients with histologically confirmed, advanced non-small cell lung cancer receiving radiation therapy evaluating biomarkers of cardiovascular stress, inflammation and vascular dysfunction.  Joshua Mitchell, MD.  National Heart, Lung and Blood Institute.
  • ICI ASSOCIATED MYOCARDITIS:  Characterization of heart tissue from patients with immune checkpoint inhibitor-associated myocarditis.  Jesus Jimenez, MD, Ph.D.  Washington University.
  • PATISIRAN EXPANDED ACCESS:  Expanded access protocol to provide patisiran to patients with transthyretin-mediated amyloidosis with cardiomyopathy. Joshua Mitchell, MD. Alnylam Pharmaceuticals, Inc.
  • PROACT:  Evaluation of MyoStrain® sequences with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.  Joshua Mitchell, MD.  Myocardial Solutions, Inc.
  • SURVIVE Registry: Cardiovascular toxicity in cancer and improvement in recovery registry.  Joshua Mitchell, MD
  • TACTIC:  A study of patients with HER-2 positive breast cancer receiving HER-2 directed therapy evaluating the timing of carvedilol initiation as an agent to reduce the incidence of LVEF decline.  Joshua Mitchell, MD.  Mayo Clinic
  • Transcutaneous Pacing (TCP) Pilot Study – EP Lab. Marye Gleva MD. Washington University
  • RESTART Study: Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion in Afib patients. Daniel Cooper MD. Washington University
  • LIBREXIA-AF: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation. Marye Gleva MD. Washington University
  • VIBRANT-AF: Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation. Daniel Cooper MD. Washington University
Electrophysiology
  • 3D MODEL:  Creation and validation of a 3D microphysiological disease model of human atrial conduction.  Timothy Smith, DPhil., MD.  Washington University.
  • CNCR REGISTRY:  A multi-center registry looking at patient outcomes for patients treated with cardiac radioablation.  Pamela Samson, MD.  Washington University. 
  • FACT-CRT:  Factors associated with response to cardiac resynchronization therapy in heart failure patients with non-LBBB ECG pattern.  Marye Gleva, MD.  University of Rochester.
  • IVTCC:  A multicenter ventricular tachycardia catheter ablation registry.  Daniel Cooper, MD.  UCLA.
  • LEADR:  Lead evaluation for defibrillation and reliability.  Timothy Smith DPhil., MD.  Medtronic.
  • MECHANISTIC BASIS OF CARDIAC IRRADIATION:  Mechanistic basis of cardiac irradiation as a therapy for ventricular tachycardia.  Stacey Rentschler, MD, PhD.  Washington University.
  • LIBREXIA AF:  A phase 3 study evaluating the safety and efficacy of milvexian versus apixaban in subjects with atrial fibrillation.   Marye Gleva, MD.  Janssen  Pharmaceuticals.
  • MVET/PERSONALIZING CLASS I ANTI-ARRHYTHMIC DRUG THERAPY:  Mexiletine ventricular tachycardia registry.  Jennifer Silva, MD., Jonathan Moreno MD, PhD, Jon Silva PhD, FAHA.  Washington University.
  • PAN:  Medtronic product surveillance registry.  Mitchell Faddis, MD, Ph.D.  Medtronic.
  • RADIATE-VT:  A study evaluating the safety and efficacy of cardiac radioablation compared to catheter ablation in patients with ventricular tachycardia. Daniel Cooper, MD.  Varian Medical Systems. (pending)
  • RESTART:  Re-ablation using a tailored approach targeting EGM-dispersion.  Daniel Cooper, MD.  Volta Medical.
  • SYNC AV:  A multicenter trial determining whether cardiac resynchronization therapy devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT.  Timothy Smith, DPhil., MD.  Abbott.
  • TAILORED AF:  Tailored versus anatomical ablation strategy for persistent AF.  Daniel Cooper, MD.  Volta Medical.
  • TRAVERSE:   Transseptal versus retrograde approach for ablation procedures involving left-sided arrhythmias (VT and PVC) to reduce emboli and neurocognitive decline in adults.   Daniel Cooper, MD.  UCSF.